Recently, an IVD company in Shenzhen gave its employees a 10-month long vacation because of "insufficient orders, which led to difficulties in the company's operation", and it was on the hot search.
According to the "Holiday Notice" circulating on the Internet, Shenzhen Huamaixing Micro Medical Technology *** will give some employees a holiday from July 1, 2023 until the end of April 2024, with a time span of up to 10 months.
As for the reason for the holiday, the company bluntly pointed out that it was because"The lack of orders has led to difficulties for the company
According to ** report, some employees of the company said to the outside world: the company is still at work, and there is no so-called shutdown. In fact, the company has given the first batch of employees a four-month holiday since July. By the end of October, the first batch of employees did not leave on their own in July, and then went on holiday with the second batch of employees until the end of April 2024. Employees who are on vacation can survive as long as they can, and if they can't stay up, they will find a job and leave on their own.
From a legal point of view, arranging an employee to take a long vacation, as long as the company provides him with the minimum wage, living expenses + social security, it is not illegal, and if the employee can't stand his resignation, the company does not have to bear the liability for compensation. Therefore, the above-mentioned practice is suspected of dismissing employees in disguise to achieve the purpose of not paying severance or compensation.
Judging from another arbitration application that was announced, Huamai Xingwei's business condition is not good, and it did not start in 2023.
The arbitration shows,Huamai Xingwei refused to pay year-end bonuses to employees because of "poor business conditions in 2019 and 2020", triggering arbitration of employees.
According to public information, Huamaixing Micro was established in 2014, deeply engaged in the microfluidic chemiluminescence track, focusing on the research and development, production, sales and service of IVD products, and is committed to providing high-quality POCT diagnostic products for the global medical market.
Microfluidic chemiluminescence, commonly known as "small luminescence", was once a popular track in the field of IVD.
Judging from the development history of Huamai Xingwei alone, the company has successfully obtained investment from investment institutions for many times.
From public data, it can be seen that Huamai Xingwei has completed a round of financing almost every year (except for 2020) in the 7 years from 2015 to 2021, which can be described as the darling of the capital market.
However, it should also be noted that the above time period is also a few years when the domestic "small luminous" market gradually tends to involution, and many players such as Shenzhen Tianshen (Wanfu), Shenzhen Tianchen, Chengdu Aixing, Beijing Meilian Tech, Renmai, Zecheng, Yiman, Huamai Xingwei, Baiming, Ruilai, Wanfu, Norman, Mingde Biotechnology and many other players have emerged.
Even Antu Biotechnology and Yahuilong, which are big players in the industry, have also begun to get involved in the field of small light.
The intensity of competition can be imagined.
"Small Luminescence", as the previous tuyere track, has a shortage of orders in such a short period of time, which also shows that there has been a situation of oversupply in this field.
In fact, this is just a microcosm of the current state of involution in the IVD field.
The IVD field has given birth to the largest number of listed companies in the pharmaceutical industry, and it is also the segment with the highest degree of homogeneity and the most fierce competition.
In the three years of the epidemic, the IVD companies that have seized the opportunity to make a lot of money have a huge amount of cash in their accounts that they never dreamed of before, and they have enough impulse and strength to smash channels and products, which will undoubtedly push the involution of the industry to a higher level.
After years of rapid development, there are more than 2,000 IVD companies in China
*: Pharmaceutical Investment Tribe.